Related Experiment Videos

Recombinant factor VIIa in an infant with haemophilia A and inhibitors

L Tengborn1, B Kjellman, P O Elfstrand

  • 1Section of Coagulation Disorders, Sahlgren's Hospital, Göteborg, Sweden.

Insights

Severe hemophilia A bleeding in a child was treated successfully with recombinant factor VIIa after standard treatments failed due to factor VIII antibodies. This approach effectively controlled hemorrhage without complications.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Coagulation Disorders

Background:

  • Severe hemophilia A is a rare inherited bleeding disorder.
  • Factor VIII concentrate and tranexamic acid are standard treatments.
  • Development of inhibitors (antibodies) to factor VIII complicates management.

Observation:

  • A 16-month-old boy with severe hemophilia A experienced persistent gingival bleeding post-trauma.
  • Standard treatment with factor VIII concentrate and tranexamic acid was ineffective.
  • Inhibitors to factor VIII were detected in the patient.

Findings:

  • Treatment with recombinant factor VIIa at 60-90 micrograms/kg body weight, administered four to eight times daily, was initiated.
  • Combined with local hemostatic measures, recombinant factor VIIa successfully controlled the gingival bleeding.
  • No adverse events or complications were observed during or after treatment.

Implications:

  • Recombinant factor VIIa is an effective alternative treatment for hemophilia A patients with high-titer inhibitors.
  • This case highlights the importance of monitoring for inhibitor development in hemophilia patients.
  • Successful management of bleeding episodes in inhibitor-positive hemophilia patients is achievable with advanced therapies.

Related Concept Videos